(1) 新型靶向药物合成研究
(2) 新型小分子免疫调节剂药物研究

（1）国家重点实验室重点任务， LG202103-02-08，以Sting为靶点的候选新药及其机制研究 ， 2021/11-2022/10 ， 250万，主持。
（2）国家高技术研究发展计划(863计划)，2003AA2Z3530、兼有心血管作用的降糖药物设计合成及活性研究，2003/01-2006/12，20万，结题，主持。
（3）南京市回国人员基金，2007，具有抗肿瘤活性的1，4取代哌啶类化合物的设计、合成与生物活性研究，2007/01-2008/12、1.5万，结题，主持。
（4）国家重大专项，2013ZX09102013,新型降血糖药物G004的临床前研究,2013.1-2015.12、288万,结题,子课题负责人。
（5）江苏省产学研联合创新基金前瞻性联合研究项目，BY2011158，2011/01-2013/12、50万，结题，参与。
（6）国家自然科学基金项目，30973638、G004抗TXA2受体介导的心血管并发症机制及受体作用模式、2009/01-2012/12、34万，结题，参与。
（7）国家重大专项，2009ZX09103-094、新型降血糖药物G004的研究开发、2009/01-2012/12，141万，结题，，课题副组长。

1.Yifei Yang, Pan Chen, Leilei Zhao, Bing Zhang, Changliang Xu*, Huibin Zhang*, Jinpei Zhou*. Design, synthesis and biological evaluation of imidazolopyridone derivatives as novel BRD4 inhibitors. Bioorganic & Medicinal Chemistry, 29(2021)115857 IF3.641
2.Xinrui Yuan, Hong Bu, Jinpei Zhou*, Chao-Yie Yang,* and Huibin Zhang*. Recent Advances of SHP2 Inhibitors in Cancer Therapy: Current Development and Clinical Application, J Med Chem, 63 (2020): 11368-11396. IF6.205
3.Jian Zhang, Pan Chen, Peiyu Zhu, Peiyuan Zheng, Tao Wang, Lixun Wang, Changliang Xu*, Jinpei Zhou*, Huibin Zhang*. Development of small-molecule BRD4 degraders based on pyrrolopyridone derivative, Bioorg. Chem, 99 (2020): 103817. IF4.831
4.Yifei Yang, Lincheng Fang, Pan Chen, Huibin Zhang,* and Jinpei Zhou*. Identification of 3,5-Dimethylisoxazole Derivatives as BRD4 Inhibitors for the Treatment of Colorectal Cancer, ACS Med Chem Lett, 11 (2020): 2174-2181. IF3.975,
5.Yifei Yang‡, Zhenwei Wu‡, Pan Chen, Peiyuan Zheng, Huibin Zhang*, Jinpei Zhou**. Proteolysis-targeting chimeras mediate the degradation of bromodomain and extra-terminal domain proteins, Future Med Chem, 12 (2020): 1669-1683. IF3.607
6.Qiangqiang Wei, Liankuo Mei, Pan Chen, Xinrui Yuan, Huibin Zhang*, Jinpei Zhou*. Design, synthesis and biological evaluation of novel chroman derivatives as non-selective acetyl-CoA carboxylase inhibitors, Bioorg Chem, 101 (2020): 103943. IF4.831
7.Shi Cai, Xiaojun Yang, Pan Chen , Xueting Liu, Jinpei Zhou*, Huibin Zhang*. Design, synthesis and biological evaluation of bicyclic carboxylic acid derivatives as IDO1 inhibitors, Bioorg. Chem. 2020 Jan;94:103356. IF4.831
8.Xialin Zhu, Yun Chen, Xu Xu, Xiaoju Xu, Yin Lu, Xi Huang, Jinpei Zhou* , Lihong Hu, Jiaying Wang*, Xu Shen*. SP6616 as a Kv2.1 inhibitor efficiently ameliorates peripheral neuropathy in diabetic mice. EbioMedicine. 2020 Nov;61:103061. IF5.736
9.Xinrui Yuan, Hanshu Wu, Hong Bu, Jinpei Zhou*, Huibin Zhang*.Targeting the immunity protein kinases for immuno-oncology. European Journal of Medicinal Chemistry. 2019,163:413-427 IF 4.833
10.Yifei Yang, Pan Chen, Leilei Zhao, Fangqing Zhang, Bing Zhang, Changliang Xu*, Huibin Zhang*, Jinpei Zhou*. Exploiting the 7-methylimidazo[1,5-a]pyrazin-8(7H)-one scaffold for the development of novel chemical inhibitors for Bromodomain and Extraterminal Domain (BET) family. Bioorg. Chem. 2019,90:103044 IF3.926